This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Pakalnis, A. Articles by Paolicchi, J. Search for Related Content PubMed PubMed Citation Articles by Pakalnis, A. Articles by Paolicchi, J. Social Bookmarking                         What's this?

Pediatric Migraine Prophylaxis With Divalproex

Departments of Neurology and Pediatrics, Ohio State University College of Medicine, Children's Hospital, Columbus, OH, pakalnisa{at}pediatrics.ohio-state.edu

Greg Greenberg, MD

Departments of Neurology and Pediatrics, Ohio State University College of Medicine, Children's Hospital, Columbus, OH

Miles E. Drake, JR, MD

Departments of Neurology and Pediatrics, Ohio State University College of Medicine, Children's Hospital, Columbus, OH

Juliann Paolicchi, MD

Departments of Neurology and Pediatrics, Ohio State University College of Medicine, Children's Hospital, Columbus, OH

We followed 23 patients with pediatric migraine, ranging in age from 7 to 17 years, who were treated with preventive divalproex sodium for migraine prophylaxis. Patients were evaluated for the presence or absence of comorbid psychiatric disorders or epilepsy to assess the possible differential effects of divalproex therapy. Doses ranged from 3.1 to 32.9 mg/kg/day. Seven patients had comorbid psychiatric disorders, whereas six patients had epilepsy (three rolandic, two generalized, and one indeterminate). Fifteen patients had a greater than 50% reduction in migraine; six patients became headache free. Divalproex doses used were not statistically different among the three groups. A favorable response and headache freedom were more likely in patients with migraine alone or with comorbid epilepsy, and less likely in patients with psychiatric comorbidity. Divalproex was well tolerated, and no significant side effects were reported. No notable changes were noted in behavioral problems, and patients with epilepsy were well controlled. In our cohort of patients, divalproex was most effective in patients with migraine alone or comorbid epilepsy. (J Child Neurol 2001;16:731-734).

Journal of Child Neurology, Vol. 16, No. 10, 731-734 (2001)
DOI: 10.1177/088307380101601005


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				A. Unalp, N. Uran, and A. Ozturk Comparison of the Effectiveness of Topiramate and Sodium Valproate in Pediatric Migraine J Child Neurol, December 1, 2008; 23(12): 1377 - 1381. [Abstract] [PDF]

				A. Pakalnis Current Therapies in Childhood and Adolescent Migraine J Child Neurol, November 1, 2007; 22(11): 1288 - 1292. [Abstract] [PDF]

				L. S Eiland, L. S Jenkins, and S. H Durham Pediatric Migraine: Pharmacologic Agents for Prophylaxis Ann. Pharmacother., July 1, 2007; 41(7): 1181 - 1190. [Abstract] [Full Text] [PDF]

				R. Sankar Initial treatment of epilepsy with antiepileptic drugs: Pediatric issues Neurology, November 23, 2004; 63(10_suppl_4): S30 - S39. [Abstract] [Full Text]

				F Galli, L Patron, P. Russo, O Bruni, L. Strambi, and V Guidetti Chronic Daily Headache in Childhood and Adolescence: Clinical Aspects and a 4-Year Follow-up Cephalalgia, October 1, 2004; 24(10): 850 - 858. [Abstract] [Full Text] [PDF]